FCA: Forget Chemoimmunotherapy with Alemtuzumab?

FCA: forget chemoimmunotherapy with alemtuzumab?

The monoclonal antibody targeting CD52, alemtuzumab, has a more potent antileukemic activity compared with the antibody targeting CD20, rituximab. CLL cells express more CD52 than CD20.3 Finally, the combination of fludarabine with alemtuzumab (FA) was shown to be effective and safe.4,5 Hence, it seemed a logical step to combine alemtuzumab with FC chemotherapy, the most efficient backbone of c...

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) is associated with superior overall survival (OS) for patients with chronic lymphocytic leukemia (CLL). Alemtuzumab (A) was added to FCR (CFAR) in a phase 2 trial for high-risk untreated patients < 70 years with serum β-2 microglobulin (β2M) ≥ 4 mg/L. Sixty patients were enrolled; median age was 59 years (range...

CLINICAL TRIALS AND OBSERVATIONS Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) is associated with superior overall survival (OS) for patients with chronic lymphocytic leukemia (CLL). Alemtuzumab (A) was added to FCR (CFAR) in a phase 2 trial for high-risk untreated patients < 70 years with serum -2 microglobulin ( 2M) > 4 mg/L. Sixty patients were enrolled; median age was 59 years (range,...

Induction chemoimmunotherapy.

Unix Systems Monitoring with FCA

There are many existing software tools for identifying specific and severe IT security threats (virus checkers, firewalls). But it is more difficult to detect less severe and more general problems, such as disclosure of sensitive or private data. In theory, security problems could be detected with existing tools, but the amount of information provided is often too overwhelming. FCA is a promisi...